Study Shows Blood Test Predicts Breast Cancer Recurrence Years Before Clinical Symptoms
Monitoring circulating tumor DNA dynamics outperformed standard markers for predicting survival and relapse in early-stage patients.
Category: Cancer
Cancer
Latest
Cancer
Latest
DELFI Diagnostics Receives New York State Approval for Lung Cancer Blood Test
The authorization from the New York State Department of Health makes the screening test available in all 50 states.
Cancer
Latest
ctDNA Blood Test May Help Guide Treatment Selection for Spreading Cancer
Research presented at ESTRO 2026 suggests circulating tumor DNA can identify which patients will benefit from combined radiation and drug therapy.
FDA Grants Breakthrough Designation to AI Bladder Cancer Prognostic Test
The FDA has granted Breakthrough Device Designation to Valar Labs’ Vesta Bladder Risk Stratify Dx, the first AI-powered digital pathology prognostic test for bladder cancer.
Read More
Blood Test Outperforms Ultrasound in Early Liver Cancer Detection, Study Finds
A multicenter clinical trial found the HelioLiver blood test detected early-stage liver cancer with 71.9% sensitivity, outperforming ultrasound’s 36.8%.
Read More
Genotyping Assay That Identifies Genetic Risk for Chemotherapy Side Effects Launches
Yourgene Health has launched the Yourgene Insight DPYD assay, expanding detection to 19 variants for DPD deficiency screening in cancer patients receiving 5-fluorouracil, with same-day results and initial Research Use Only availability.
Read More
Moffitt Cancer Center to Scale Digital Pathology Data Management
Moffitt Cancer Center is partnering with Dicom Systems to scale digital pathology data management using the Unifier Platform, enabling standardized imaging workflows and supporting high-volume slide routing of up to 85,735 slides per day.
Read More
Medicare Expands Coverage for Cancer Immunotherapy Monitoring Test
CMS has expanded Medicare coverage for Personalis’ NeXT Personal MRD test, now allowing immunotherapy monitoring in late-stage solid tumor patients, supported by recent clinical evidence from Vall d’Hebron Institute of Oncology.
Read More
FDA Clears New Genomic Test for Solid Tumors
The FDA has cleared Datar Cancer Genetics’ CellDx-Tissue, a genomic profiling assay that analyzes 517 cancer-associated genes from solid tumor tissue to support clinical decision-making, according to the company.
Read More
Caris Life Sciences Seeks New York State Authorization for Blood-Based Cancer Test
Caris Life Sciences has applied to the New York State Department of Health for authorization of Caris Assure, a blood-based molecular profiling test for cancer using whole exome and transcriptome sequencing of 22,000 genes.
Read More
Amplified Sciences Launches Study for Pancreatic Cyst Diagnostic Assay
Amplified Sciences has launched the PanAMP multicenter study to assess how its PanCystPro assay impacts clinical management decisions for patients with radiographically confirmed pancreatic cystic lesions.
Read More
Liquid Biopsy of Tumor Microenvironment Predicts Cancer Therapy Response
LiquidCell Dx has published research in Nature on LiquidTME, a blood-based assay that profiles the tumor microenvironment and predicts immunotherapy response, potentially offering a noninvasive alternative to tissue biopsy.
Read More
FDA Clears AI-Based Risk Stratification Tool for Breast Cancer
The FDA has cleared ArteraAI Breast, an AI-based digital pathology tool that provides same-day risk stratification for early-stage, HR-positive, HER2-negative invasive breast cancer.
Read More
Avant Genomics Raises $3M for Automated Liquid Biopsy Sample Preparation
Avant Genomics has secured over $3 million in funding to develop its Avant Source platform, which aims to automate liquid biopsy sample preparation and improve cell-free DNA recovery.
Read More
Foundation Medicine Expands Bristol Myers Squibb Deal to Develop MTAP Biomarker Test
Foundation Medicine and Bristol Myers Squibb have expanded their partnership to develop an NGS-based companion diagnostic for identifying homozygous MTAP deletions, supporting targeted therapy development in precision oncology.
Read More
GRAIL to Present New Data on Multi-Cancer Early Detection Test
Presentations will feature results from the NHS-Galleri and PATHFINDER 2 studies involving more than 174,000 participants.
Read More
Artera Receives CE Marks for AI-Powered Prostate and Breast Cancer Tests
Artera has received CE marks under EU IVDR for its AI-powered prostate and breast cancer assays, enabling clinical use of these prognostic and predictive tests in the European Union and other territories, the company announced.
Read More
A Urine Test That Could Help Predict Bladder Cancer Recurrence
Researchers have developed a urine-based liquid biopsy test that filters age-related mutations, potentially enabling more accurate prediction of bladder cancer recurrence and guiding immunotherapy decisions.
Read More
- 1
- ...
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- 152
- 153
- 154
- 155
- 156
- 157
- 158
- 159
- 160
- 161
- 162
- 163
- 164
- 165
- 166
- 167
- 168
- 169
- 170
- 171
- 172
- 173
- 174
- 175
- 176
- 177
- 178
- 179
- 180
- 181
- 182
- 183
- 184
- 185
- 186
- 187
- 188
- 189
- 190
- 191
- 192
- 193
- 194
- 195
- 196
- 197
- ...
- 198